Reportlinker Adds Product Profiles: Osteoporosis - Novel Candidates Offer the Greatest Potential
NEW YORK, June 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Product Profiles: Osteoporosis - Novel candidates offer the greatest potential
Introduction
Despite major brands losing market exclusivity increasing cost competition, the osteoporosis market remains attractive. Leading osteoporosis companies continue to promote their products and develop their franchises while drug developers strive to bring their agents to market in an attempt to meet unmet need and tap into this potentially profitable patient population
Features and benefits
* Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating osteoporosis
* Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes
* Understand how marketed brands are positioned in the osteoporosis treatment algorithm and how they are perceived by treating physicians
* Evaluate the latest drug launches and barriers to increasing market share
* Determine to what extent future therapies satisfy the main clinical unmet needs in osteoporosis treatment
Highlights
Forteo (teriparatide; Eli Lilly) further increased its class leading position after its launch in Japan in summer 2010. The biggest opportunity in the market remains for new safe and efficacious anabolic therapies, indeed several PTH analogs continue their development, in an attempt to become the first second generation PTH to reach the market.
n 2010, Prolia (denosumab) was launched in the US and EU. Initial sales were modest and Amgen and its European partner GlaxoSmithKline need to continue marketing their product aggressively as a convenient bone strengthening drug in order to increase market share.
Odanacatib (Merck & Co) is the most promising product in the pipeline due to its favorable clinical profile and Merck's market experience. However, with launch is expected only in 2015, Merck will face the large challenge of penetrating the highly saturated and genericized antiresorptive market.
Your key questions answered
* What are the key differentiating features of approved therapies for osteoporosis and how are they used in the daily management of the disease?
* How did Prolia perform upon launch and what strategies are Amgen and GlaxoSmithKline implementing to drive market penetration
* How do key opinion leaders and prescribers perceive available treatments for osteoporosis?
* Do pipeline products address key clinical unmet needs?
* What are the comparative strengths and weaknesses of the key osteoporosis brands and pipeline candidates?
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION AND OVERVIEW
Product overview
MARKETED PRODUCT PROFILES
Fosamax/Fosamax Plus D (alendronate; Merck & Co.)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Fosamax
Clinical and commercial attractiveness
Actonel/Actonel with Calcium (risedronic acid; Sanofi/Warner Chilcott)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Actonel
Clinical and commercial attractiveness
Bonviva/Boniva (ibandronic acid; Roche/GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Bonviva
Clinical and commercial attractiveness
Aclasta/Reclast (zoledronic acid; Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Aclasta
Clinical and commercial attractiveness
Forteo (teriparatide; Eli Lilly)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Forteo
Clinical and commercial attractiveness
Prolia (denosumab; Amgen/GlaxoSmithKline/Daiichi Sankyo)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Evista (raloxifene; Eli Lilly)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Evista
Clinical and commercial attractiveness
Conbriza/Viviant (bazedoxifene; Pfizer/Almirall)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Protelos (strontium ranelate; Servier)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Protelos
Clinical and commercial attractiveness
Edirol (eldecalcitol; Chugai/Taisho)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Other marketed drugs for osteoporosis
Bonoteo/Recalbon (minodronic acid; Astellas/Ono Pharmaceutical)
Preotact (full-length PTH 1-84; NPS/Nycomed)
Miacalcic (calcitonin-salmon; Novartis)
Fortical (calcitonin-salmon; UniGene)
PIPELINE PRODUCT PROFILES
Odanacatib (MK0822; Merck & Co.)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
ZT-031 (hPTH1-31; Zelos Therapeutics)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
ZP-PTH (hPTH1-34; Zosano Pharma)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
BA058 (PTH peptide fragment; Radius)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
EX101 (alendronate; EffRx/Nycomed)
Drug profile
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Almerol (alendronate; Merrion)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Aprela (bazedoxifene with conjugated estrogens; Pfizer)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
SMC021 (salmon calcitonin; Novartis)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Capsitonin (BN-002; Bone Medical)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
NBS101 (strontium malonate; Osteologix)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other drugs in development for osteoporosis
Fablyn (lasofoxifene; Pfizer/Ligand)
MK5442 (Merck & Co.)
Anti-sclerostin (AMG785; Amgen)
2MD/DP001 (vitamin D analog; Deltanoid Pharma)
San134 (glucagon-like peptide-2; Sanos Bioscience)
ACE-011 (activin inhibitor; Acceleron Pharma)
ViaDerm-hPTH (PTH peptide fragment; TransPharma/Eli Lilly)
CaPTHymone (PTH analog; Bone Medical)
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
Conferences attended
APPENDIX A – SURVEY INFORMATION
Physician research methodology
Physician sample breakdown
US
Japan
France
Germany
Italy
Spain
UK
Product Profiles (section 5)
APPENDIX B
Market definition
PharmaVitae Explorer database
Contributing experts
Conferences attended
Report methodology
To order this report:
Pathology Industry: Product Profiles: Osteoporosis - Novel candidates offer the greatest potential
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article